Elevance Health Shares Rise as Third-Quarter Earnings Beat Estimates and 2026 Guidance Increases
Elevance Health (ELV) reported Q3 2026 earnings of $6.99 per share, beating estimates of $4.70, and revenue of $50.4B, up 0.7% YoY. The company raised its 2026 adjusted EPS guidance to at least $29.00 and increased its operating cash flow guidance to $6.5B. Membership declined by 487,000, but revenue grew in both Health Benefits and Carelon segments.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise provide a clear catalyst for short-term price movement and may influence analyst revisions.
Market read
The report is a primary disclosure of earnings and guidance, offering actionable insight for traders.
What to watch
The improvement in benefit expense ratio may be temporary if enrollment continues to fall.
Background
Elevance Health is a major U.S. health insurer with diversified insurance and care services businesses.
Ticker impact
Elevance Health reported Q3 2026 earnings that beat estimates and raised full-year earnings and cash flow guidance.
likely modest upside as the market prices in the earnings beat and higher guidance
The beat was sizable ($6.99 vs $4.70) and guidance was lifted, which typically supports the stock.
Market effects
Health insurance sector may see a lift as Elevance's results suggest stronger premium yields.
U.S. healthcare stocks could benefit from the upbeat earnings trend.
Limited to U.S. markets; no direct global impact.
Counterpoint
Membership declines and lower enrollment could pressure margins despite the earnings beat.
Key entities
- personGail K. Boudreaux
President and CEO of Elevance Health, provided commentary on results.
